BACKGROUND AND OBJECTIVES:Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, reduces bioavailability of nitric oxide and induces endothelial dysfunction. This dimethylated amino acid accumulates in chronic kidney disease and may be involved in the pathophysiology of cardiovascular disease (CVD) in this population. DESIGN, SETTINGS, PARTICIPANTS, & METHODS: The Modification of Diet in Renal Disease Study was a randomized, controlled trial conducted between 1989 and 1993. We measured ADMA in frozen samples collected at baseline (n = 820) and obtained survival status, up to December 31, 2000, from the National Death Index. We examined the relationship of ADMA with prevalent CVD and performed multivariable Cox models to examine the relationship of ADMA with all-cause and CVD mortality. RESULTS:Mean (SD) age was 52 (12) yr, GFR was 32 +/- 12 ml/min per 1.73 m(2), and ADMA was 0.70 +/- 0.25 micromol/L. A 1-SD increase in ADMA was associated with a 31% increased odds of prevalent CVD in an adjusted logistic regression model. During the 10-yr follow-up period, 202 (25%) participants died of any cause, 122 (15%) from CVD, and 545 (66%) reached kidney failure. In multivariable Cox models, a 1-SD increase in ADMA was associated with a 9% increased risk for all-cause and 19% increased risk for CVD mortality. CONCLUSIONS: In this cohort of patients with predominantly nondiabetic, stages 3 to 4 chronic kidney disease, there was a strong association of ADMA with prevalent CVD and a modest association with all-cause and CVD mortality.
RCT Entities:
BACKGROUND AND OBJECTIVES: Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, reduces bioavailability of nitric oxide and induces endothelial dysfunction. This dimethylated amino acid accumulates in chronic kidney disease and may be involved in the pathophysiology of cardiovascular disease (CVD) in this population. DESIGN, SETTINGS, PARTICIPANTS, & METHODS: The Modification of Diet in Renal Disease Study was a randomized, controlled trial conducted between 1989 and 1993. We measured ADMA in frozen samples collected at baseline (n = 820) and obtained survival status, up to December 31, 2000, from the National Death Index. We examined the relationship of ADMA with prevalent CVD and performed multivariable Cox models to examine the relationship of ADMA with all-cause and CVD mortality. RESULTS: Mean (SD) age was 52 (12) yr, GFR was 32 +/- 12 ml/min per 1.73 m(2), and ADMA was 0.70 +/- 0.25 micromol/L. A 1-SD increase in ADMA was associated with a 31% increased odds of prevalent CVD in an adjusted logistic regression model. During the 10-yr follow-up period, 202 (25%) participants died of any cause, 122 (15%) from CVD, and 545 (66%) reached kidney failure. In multivariable Cox models, a 1-SD increase in ADMA was associated with a 9% increased risk for all-cause and 19% increased risk for CVD mortality. CONCLUSIONS: In this cohort of patients with predominantly nondiabetic, stages 3 to 4 chronic kidney disease, there was a strong association of ADMA with prevalent CVD and a modest association with all-cause and CVD mortality.
Authors: Markus C Stühlinger; Fahim Abbasi; James W Chu; Cindy Lamendola; Tracey L McLaughlin; John P Cooke; Gerald M Reaven; Philip S Tsao Journal: JAMA Date: 2002-03-20 Impact factor: 56.272
Authors: Robert J Nijveldt; Paul A M Van Leeuwen; Coen Van Guldener; Coen D A Stehouwer; Jan A Rauwerda; Tom Teerlink Journal: Nephrol Dial Transplant Date: 2002-11 Impact factor: 5.992
Authors: Carmine Zoccali; Francesca Mallamaci; Renke Maas; Francesco A Benedetto; Giovanni Tripepi; Lorenzo S Malatino; Alessandro Cataliotti; Ignazio Bellanuova; Rainer Böger Journal: Kidney Int Date: 2002-07 Impact factor: 10.612
Authors: Jennifer J DuPont; Meghan G Ramick; William B Farquhar; Raymond R Townsend; David G Edwards Journal: Am J Physiol Renal Physiol Date: 2014-04-23
Authors: Jing Chen; L Lee Hamm; Joshua D Bundy; Damodar R Kumbala; Shirisha Bodana; Sehgal Chandra; Chung-Shiuan Chen; Charlton C Starcke; Yajun Guo; Caroline M Schaefer; Eva Lustigova; Erin Mahone; Aarti M Vadalia; Terra Livingston; Katherine Obst; Jesus Hernandez; Syed Rizwan Bokhari; Myra Kleinpeter; Arnold B Alper; Ivo Lukitsch; Hua He; David C Nieman; Jiang He Journal: Clin J Am Soc Nephrol Date: 2020-10-06 Impact factor: 8.237
Authors: R Kaseda; Y Tsuchida; J L Gamboa; J Zhong; L Zhang; H Yang; A Dikalova; A Bian; S Davies; A F Fogo; M F Linton; N J Brown; T A Ikizler; V Kon Journal: Nutr Metab Cardiovasc Dis Date: 2018-03-08 Impact factor: 4.222
Authors: Insa E Emrich; Adam M Zawada; Jens Martens-Lobenhoffer; Danilo Fliser; Stefan Wagenpfeil; Gunnar H Heine; Stefanie M Bode-Böger Journal: Clin Res Cardiol Date: 2017-11-03 Impact factor: 5.460